DK1019089T3 - Langtidsvirkende lægemidler og farmaceutiske præparater der omfatter disse - Google Patents
Langtidsvirkende lægemidler og farmaceutiske præparater der omfatter disseInfo
- Publication number
- DK1019089T3 DK1019089T3 DK97933828T DK97933828T DK1019089T3 DK 1019089 T3 DK1019089 T3 DK 1019089T3 DK 97933828 T DK97933828 T DK 97933828T DK 97933828 T DK97933828 T DK 97933828T DK 1019089 T3 DK1019089 T3 DK 1019089T3
- Authority
- DK
- Denmark
- Prior art keywords
- peptide
- hirudin
- conjugates
- long
- pharmaceutical compositions
- Prior art date
Links
- 239000003509 long acting drug Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 6
- 108010007267 Hirudins Proteins 0.000 abstract 2
- 102000007625 Hirudins Human genes 0.000 abstract 2
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 abstract 2
- 229940006607 hirudin Drugs 0.000 abstract 2
- 108010038807 Oligopeptides Proteins 0.000 abstract 1
- 102000015636 Oligopeptides Human genes 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 150000002634 lipophilic molecules Chemical class 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL11902996A IL119029A0 (en) | 1996-08-07 | 1996-08-07 | Long-acting drugs and pharamaceutical compositions comprising them |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1019089T3 true DK1019089T3 (da) | 2006-03-13 |
Family
ID=11069166
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK97933828T DK1019089T3 (da) | 1996-08-07 | 1997-08-05 | Langtidsvirkende lægemidler og farmaceutiske præparater der omfatter disse |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US6504005B1 (enExample) |
| EP (1) | EP1019089B1 (enExample) |
| JP (1) | JP4416184B2 (enExample) |
| KR (1) | KR20000029806A (enExample) |
| CN (1) | CN1227501A (enExample) |
| AT (1) | ATE308998T1 (enExample) |
| AU (1) | AU725468B2 (enExample) |
| BR (1) | BR9711045A (enExample) |
| CA (1) | CA2261835C (enExample) |
| CZ (1) | CZ36999A3 (enExample) |
| DE (1) | DE69734607T2 (enExample) |
| DK (1) | DK1019089T3 (enExample) |
| ES (1) | ES2252787T3 (enExample) |
| HU (1) | HUP0000809A2 (enExample) |
| IL (3) | IL119029A0 (enExample) |
| NO (1) | NO990518L (enExample) |
| NZ (1) | NZ333845A (enExample) |
| WO (1) | WO1998005361A2 (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL139400A0 (en) * | 2000-11-01 | 2001-11-25 | Yeda Res & Dev | Long-acting cytokine derivatives and pharmaceutical compositions comprising them |
| JP2004521093A (ja) * | 2000-12-13 | 2004-07-15 | イーライ・リリー・アンド・カンパニー | グルカゴン様インスリン刺激性ペプチドを用いる長期治療計画 |
| CN101785861B (zh) * | 2001-10-19 | 2014-08-13 | 爱德士实验室公司 | 用于药理活性化合物的可控释放的可注射组合物 |
| US6946137B2 (en) * | 2001-10-19 | 2005-09-20 | Idexx Laboratories, Inc. | Methods for the controlled delivery of pharmacologically active compounds |
| US20030171285A1 (en) * | 2001-11-20 | 2003-09-11 | Finn Rory F. | Chemically-modified human growth hormone conjugates |
| BE1015608A6 (fr) * | 2003-07-15 | 2005-06-07 | Messadek Jallal | Traitement des arterites. |
| JP4033382B2 (ja) * | 2002-04-08 | 2008-01-16 | 久光製薬株式会社 | インスリン投与装置 |
| WO2004064972A2 (en) * | 2003-01-16 | 2004-08-05 | Hk Pharmaceuticals, Inc. | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions |
| EP1620118B1 (en) | 2003-04-08 | 2014-06-18 | Yeda Research And Development Co., Ltd. | Reversible pegylated drugs |
| EP1615632B1 (fr) * | 2003-04-17 | 2006-12-06 | Jallal Messadek | Formulations orales flottantes pour la liberation controlee de la betaine |
| JP4463814B2 (ja) | 2003-08-05 | 2010-05-19 | ノボ ノルディスク アクティーゼルスカブ | 新規のインスリン誘導体 |
| BE1016128A6 (fr) * | 2004-07-22 | 2006-03-07 | Messadek Jallal | Combinaisons therapeutiques |
| US7282487B2 (en) * | 2004-10-28 | 2007-10-16 | Idexx Laboratories | Method for treating bacterial infections in horses or pigs with tilmicosin |
| WO2006050581A2 (en) * | 2004-11-10 | 2006-05-18 | Jallal Messadek | Betaine as agent against arthropod - or mosquito -borne diseases |
| ATE540690T1 (de) * | 2005-04-27 | 2012-01-15 | Jallal Messadek | Insulinkombinationen |
| DK1969004T3 (da) | 2005-12-28 | 2011-11-28 | Novo Nordisk As | Insulinsammensætninger og metode til at lave en sammensætning |
| EP2167032B1 (en) | 2007-06-13 | 2019-08-07 | Novo Nordisk A/S | Pharmaceutical formulation comprising an insulin derivative |
| WO2009065193A1 (en) * | 2007-11-21 | 2009-05-28 | Jallal Messadek | Treatment of aspirin resistance with betaine and/or betaine enriched molasses |
| KR20110004366A (ko) | 2008-03-18 | 2011-01-13 | 노보 노르디스크 에이/에스 | 프로테아제 안정화되고, 아실화된 인슐린 유사체 |
| CN102076331B (zh) | 2008-06-26 | 2013-12-18 | 普罗林科斯有限责任公司 | 具有可控的药物释放速率的前药和药物-大分子轭合物 |
| US20110166063A1 (en) * | 2008-09-19 | 2011-07-07 | Nektar Therapeutics | Polymer conjugates of therapeutic peptides |
| EP2344200A2 (en) * | 2008-09-19 | 2011-07-20 | Nektar Therapeutics | Modified therapeutics peptides, methods of their preparation and use |
| US9274122B2 (en) | 2008-10-21 | 2016-03-01 | Baxalta Incorporated | Methods for determining active ingredients in pro-drug PEG protein conjugates with releasable PEG reagents (in vitro de-pegylation) |
| WO2010049488A1 (en) * | 2008-10-30 | 2010-05-06 | Novo Nordisk A/S | Treating diabetes melitus using insulin injections with less than daily injection frequency |
| AU2010220324A1 (en) | 2009-03-05 | 2011-09-01 | Ascendis Pharma As | Interferon alpha carrier prodrugs |
| WO2011013128A2 (en) | 2009-07-31 | 2011-02-03 | Yeda Research And Development Co. Ltd. | Vectors for delivery of neurotherapeutics to the central nervous system |
| CN103025165B (zh) * | 2010-05-05 | 2016-06-08 | 普罗林科斯有限责任公司 | 自大分子共轭物的控释 |
| DK2632478T3 (da) | 2010-10-27 | 2019-10-07 | Novo Nordisk As | Behandling af diabetes melitus under anvendelse af insulinindsprøjtninger indgivet med varierende indsprøjtningsintervaller |
| EP2490378B1 (en) | 2011-02-18 | 2014-07-09 | NTT DoCoMo, Inc. | Apparatus and method for determining a control unit using feasibility requests and feasibility responses |
| US10166295B2 (en) | 2011-06-02 | 2019-01-01 | Opko Biologics Ltd. | Pegylated OXM variants |
| EP2714070B1 (en) | 2011-06-02 | 2024-03-20 | OPKO Biologics Ltd. | Long-acting glp-1/glucagon receptor agonists |
| AU2013247047A1 (en) | 2012-04-11 | 2014-10-23 | Novo Nordisk A/S | Insulin formulations |
| CN104684576B (zh) | 2012-06-04 | 2019-08-06 | 奥普科生物制品有限公司 | 聚乙二醇化的oxm变体 |
| US20150111820A1 (en) | 2012-07-09 | 2015-04-23 | Novo Nordisk A/S | Novel use of insulin derivatives |
| EP2991672A1 (en) | 2013-04-30 | 2016-03-09 | Novo Nordisk A/S | Novel administration regime |
| BR112019011761A2 (pt) | 2016-12-16 | 2019-11-05 | Novo Nordisk As | composições farmacêuticas contendo insulina |
| US10335464B1 (en) | 2018-06-26 | 2019-07-02 | Novo Nordisk A/S | Device for titrating basal insulin |
| US12441776B2 (en) | 2018-11-30 | 2025-10-14 | Eirgen Pharma Ltd. | Oxyntomodulin peptide analog formulations |
| KR20210126088A (ko) | 2019-02-11 | 2021-10-19 | 옵코 바이오로직스 리미티드 | 지속성 glp-2 유사체 |
| US12343383B2 (en) | 2019-07-12 | 2025-07-01 | Novo Nordisk A/S | High concentration insulin formulation |
| CN113773398B (zh) * | 2020-06-10 | 2023-05-23 | 宁波鲲鹏生物科技有限公司 | 一种德谷胰岛素衍生物及其应用 |
| CN117551008B (zh) * | 2023-11-10 | 2025-10-17 | 沈阳药科大学 | 一种去铁胺偶联物及其制备方法和应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU906340D0 (en) | 1986-10-13 | 1991-04-29 | Sandoz Ag | Synthesis in solid phase for producing peptonic alcohols |
| GB8717446D0 (en) | 1987-07-23 | 1987-08-26 | Merck Sharp & Dohme | Chemical compounds |
| US6313094B1 (en) * | 1990-12-11 | 2001-11-06 | Japan Energy Corporation | β-amino-α-hydroxycarboxylic acid derivatives and HIV protease inhibitors |
| JPH0687887A (ja) * | 1992-08-19 | 1994-03-29 | Upjohn Co:The | ペプチドのエナミン誘導体およびそれをプロドラッグとして含有するペプチド製剤 |
| EP0679658A4 (en) | 1993-06-25 | 1997-06-04 | Kyowa Hakko Kogyo Kk | Endothelin-antagonizing peptide. |
| US5880131A (en) * | 1993-10-20 | 1999-03-09 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
| DE4437604A1 (de) | 1994-10-21 | 1996-04-25 | Basf Ag | Konjugate aus einem Poly- oder Oligopeptid und einer niedermolekularen lipophilen Verbindung |
| US5955434A (en) | 1995-02-09 | 1999-09-21 | Brigham & Women's Hospital | Gel-forming polypeptide derivatives |
| WO1996030267A2 (en) * | 1995-03-30 | 1996-10-03 | Southpac Trust International, Inc. | Self-erecting container which is collapsible to be substantially flat |
| US5688992A (en) | 1995-03-31 | 1997-11-18 | The United States Of America As Represented By The Department Of Health And Human Services | O-malonyltryrosyl compounds, O-malonyltryrosyl compound-containing peptides, and use thereof |
| US5846934A (en) * | 1996-02-20 | 1998-12-08 | American Cyanamid Company | Pure somatostatin antagonist and methods of use thereof |
| US6057297A (en) * | 1996-08-06 | 2000-05-02 | Polifarma S.P.A. | Inhibitor compounds of zinc-dependent metalloproteinases associated with pathological conditions, and therapeutic use thereof |
-
1996
- 1996-08-07 IL IL11902996A patent/IL119029A0/xx unknown
-
1997
- 1997-08-05 BR BR9711045A patent/BR9711045A/pt not_active IP Right Cessation
- 1997-08-05 US US09/242,026 patent/US6504005B1/en not_active Expired - Lifetime
- 1997-08-05 CN CN97197122A patent/CN1227501A/zh active Pending
- 1997-08-05 DK DK97933828T patent/DK1019089T3/da active
- 1997-08-05 CZ CZ99369A patent/CZ36999A3/cs unknown
- 1997-08-05 WO PCT/IL1997/000265 patent/WO1998005361A2/en not_active Ceased
- 1997-08-05 JP JP50777098A patent/JP4416184B2/ja not_active Expired - Lifetime
- 1997-08-05 EP EP97933828A patent/EP1019089B1/en not_active Expired - Lifetime
- 1997-08-05 HU HU0000809A patent/HUP0000809A2/hu unknown
- 1997-08-05 ES ES97933828T patent/ES2252787T3/es not_active Expired - Lifetime
- 1997-08-05 AT AT97933828T patent/ATE308998T1/de active
- 1997-08-05 AU AU37060/97A patent/AU725468B2/en not_active Ceased
- 1997-08-05 DE DE69734607T patent/DE69734607T2/de not_active Expired - Lifetime
- 1997-08-05 CA CA002261835A patent/CA2261835C/en not_active Expired - Lifetime
- 1997-08-05 KR KR1019997000941A patent/KR20000029806A/ko not_active Withdrawn
- 1997-08-05 IL IL12827497A patent/IL128274A0/xx active IP Right Grant
- 1997-08-05 NZ NZ333845A patent/NZ333845A/xx unknown
-
1999
- 1999-01-28 IL IL128274A patent/IL128274A/en not_active IP Right Cessation
- 1999-02-04 NO NO990518A patent/NO990518L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU3706097A (en) | 1998-02-25 |
| CZ36999A3 (cs) | 1999-07-14 |
| US6504005B1 (en) | 2003-01-07 |
| JP2000515542A (ja) | 2000-11-21 |
| EP1019089B1 (en) | 2005-11-09 |
| CN1227501A (zh) | 1999-09-01 |
| EP1019089A2 (en) | 2000-07-19 |
| IL119029A0 (en) | 1996-11-14 |
| NO990518L (no) | 1999-04-06 |
| NZ333845A (en) | 2000-09-29 |
| ATE308998T1 (de) | 2005-11-15 |
| CA2261835C (en) | 2008-07-29 |
| JP4416184B2 (ja) | 2010-02-17 |
| IL128274A (en) | 2006-08-01 |
| DE69734607T2 (de) | 2006-08-03 |
| NO990518D0 (no) | 1999-02-04 |
| WO1998005361A2 (en) | 1998-02-12 |
| DE69734607D1 (de) | 2005-12-15 |
| AU725468B2 (en) | 2000-10-12 |
| CA2261835A1 (en) | 1998-02-12 |
| IL128274A0 (en) | 1999-11-30 |
| HUP0000809A2 (hu) | 2000-11-28 |
| ES2252787T3 (es) | 2006-05-16 |
| KR20000029806A (ko) | 2000-05-25 |
| BR9711045A (pt) | 1999-08-17 |
| WO1998005361A3 (en) | 1998-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1019089T3 (da) | Langtidsvirkende lægemidler og farmaceutiske præparater der omfatter disse | |
| KR960702323A (ko) | 폴리머를 사용하는 비타민 b₁₂ 흡수시스템의 증폭 (amplification of the vitamin b₁₂ uptake system using polymers) | |
| AU4162400A (en) | Derivatives of the b or z domain from staphylococcal protein a (spa) interactingwith at least one domain of human factor viii | |
| NL194828B (nl) | Somatostatinepeptiden, alsmede dergelijke somatostatinepeptiden bevattende farmaceutische preparaten. | |
| EP1027061A4 (en) | IMIN-FORMING POLYSACCHARIDES, THEIR PRODUCTION AND USE AS ADDITIVES AND IMMUNO-STIMULATING AGENTS | |
| ATE533784T1 (de) | Lösliche, einzelkettige proteine des t- zellrezeptors | |
| DE69820885D1 (de) | Peptidsequenzen als scharnierregionen in proteinen wie immunglobulinfragmenten und ihre verwendung in der heilkunde | |
| NO995891D0 (no) | LH-RH peptidanaloger, anvendelser og farmasöytiske blandinger inneholdende disse | |
| HUP0002381A3 (en) | Apolipoprotein a-1 agonist peptide derivatives, complexes thereof and pharmaceutical compositions comprising their | |
| ATE193022T1 (de) | Heparin-und sulfatid-bindende peptide vom typ 1 der wiederkehrenden sequenzen vom menschlichen thrombospondin | |
| WO1995011977A3 (en) | A NEW RIBOSOME-INACTIVATING PROTEIN ISOLATED FROM THE PLANT $i(BRYONIA DIOICA) | |
| ATE111746T1 (de) | Polymyxinkonjugate. | |
| DK1049721T3 (da) | Syntetiske polysaccharider, fremgangsmåde til fremstilling heraf og farmaceutiske præparater indeholdende disse | |
| ATE172216T1 (de) | Konjugate von calcitonin und polyethylenglycol | |
| ATE238348T1 (de) | Aus thymischen hormonen abstammende peptid konjugierte, deren verwendung als medikamente und aus deren enthaltende zusammensetzungen | |
| DE60044832D1 (de) | Niedermolekulare Peptide als Inhibitoren der Laminin/Nidogen Wechselwirkung | |
| NO894594D0 (no) | Farmasoeytiske sammensetninger omfattende labdan diterpenoid-derivater og pyrimido(6,1-a)isoquinolin-4-ono-derivater. | |
| ATE201996T1 (de) | Hirudin enthaltende pharmazeutische zusammensetzungen | |
| AU6760294A (en) | Immunotherapeutic peptides derived from toxic shock syndrome toxin-1, antibodies thereto, their uses in pharmaceutical compositions and diagnosis | |
| IT1216120B (it) | Derivati n_cicloalchilaminoetilbenzamidici, loro preparazione e composizioni farmaceutiche che li contengono. |